Impact Factor 5.511
2017 JCR, Clarivate Analytics 2018

Among the world's top 10 most-cited Immunology journals

This article is part of the Research Topic

Recent Advances in Oral Immunity

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2019.00933

BET bromodomain inhibitors suppress inflammatory activation of gingival fibroblasts and epithelial cells from periodontitis patients.

Anna Maksylewicz1, Agnieszka Bysiek1, Katarzyna B. Lagosz1, Justyna M. Macina1, Malgorzata Kantorowicz2,  Grzegorz Bereta1,  Maja Sochalska1,  Katarzyna Gawron1, Maria Chomyszyn-Gajewska2,  Jan Potempa1, 3 and  Aleksander M. Grabiec1*
  • 1Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Poland
  • 2Jagiellonian University Medical College, Poland
  • 3Department of Oral Immunology and Infectious Diseases, School of Dentistry, University of Louisville, United States

BET bromodomain proteins are important epigenetic regulators of gene expression that bind acetylated histone tails and regulate the formation of acetylation-dependent chromatin complexes. BET inhibitors suppress inflammatory responses in multiple cell types and animal models, and protect against bone loss in experimental periodontitis in mice. Here, we analyzed the role of BET proteins in inflammatory activation of gingival fibroblasts (GFs) and gingival epithelial cells (GECs). We show that the BET inhibitors I-BET151 and JQ1 significantly reduced expression and/or production of distinct, but overlapping, profiles of cytokine-inducible mediators inflammation and bone resorption in GFs from healthy donors (IL6, IL8, IL1B, CCL2, CCL5, COX2 and MMP3) and the GEC line TIGK (IL6, IL8, IL1B, CXCL10, MMP9) without affecting cell viability. Activation of mitogen activated protein kinase and nuclear factor-κB pathways was unaffected by I-BET151, as was the histone acetylation status, and new protein synthesis was not required for the anti-inflammatory effects of BET inhibition. I-BET151 and JQ1 also suppressed expression of inflammatory cytokines, chemokines and osteoclastogenic mediators in GFs and TIGKs infected with the key periodontal pathogen Porphyromonas gingivalis. Notably, P. gingivalis internalization and intracellular survival in GFs and TIGKs remained unaffected by BET inhibitors. Finally, inhibition of BET proteins significantly reduced P. gingivalis-induced inflammatory mediator expression in GECs and GFs from patients with periodontitis. Our results demonstrate that BET inhibitors may block the excessive inflammatory mediator production by resident cells of the gingival tissue and identify the BET family of epigenetic reader proteins as a potential therapeutic target in the treatment of periodontal disease.

Keywords: Periodonditis, BET bromodomain, Gingival fibroblast, Gingival epithelial cell, Porphyromonas gingivalis, I-BET151, chronic inflammation

Received: 02 Sep 2018; Accepted: 11 Apr 2019.

Edited by:

Asaf Wilensky, Hadassah Medical Center, Israel

Reviewed by:

Whasun O. Chung, University of Washington, United States
Joerg Meyle, University of Giessen, Germany  

Copyright: © 2019 Maksylewicz, Bysiek, Lagosz, Macina, Kantorowicz, Bereta, Sochalska, Gawron, Chomyszyn-Gajewska, Potempa and Grabiec. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: PhD. Aleksander M. Grabiec, Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, 30-387, Lesser Poland, Poland,